S&P 500   4,231.93 (+0.52%)
DOW   33,507.23 (+0.59%)
QQQ   326.78 (+0.26%)
AAPL   169.49 (+0.15%)
MSFT   287.91 (-0.43%)
META   179.47 (+0.63%)
GOOGL   119.57 (-0.11%)
AMZN   141.76 (-0.65%)
TSLA   869.55 (-1.53%)
NVDA   183.56 (+1.43%)
NIO   21.44 (+6.93%)
BABA   95.51 (+3.33%)
AMD   100.77 (+1.74%)
MU   63.06 (+2.70%)
T   18.09 (+0.44%)
CGC   3.23 (-1.82%)
GE   78.71 (+2.04%)
F   15.68 (+1.16%)
DIS   118.88 (+5.74%)
AMC   25.08 (+5.96%)
PYPL   99.80 (+0.90%)
PFE   48.71 (-2.48%)
NFLX   244.94 (+0.34%)
S&P 500   4,231.93 (+0.52%)
DOW   33,507.23 (+0.59%)
QQQ   326.78 (+0.26%)
AAPL   169.49 (+0.15%)
MSFT   287.91 (-0.43%)
META   179.47 (+0.63%)
GOOGL   119.57 (-0.11%)
AMZN   141.76 (-0.65%)
TSLA   869.55 (-1.53%)
NVDA   183.56 (+1.43%)
NIO   21.44 (+6.93%)
BABA   95.51 (+3.33%)
AMD   100.77 (+1.74%)
MU   63.06 (+2.70%)
T   18.09 (+0.44%)
CGC   3.23 (-1.82%)
GE   78.71 (+2.04%)
F   15.68 (+1.16%)
DIS   118.88 (+5.74%)
AMC   25.08 (+5.96%)
PYPL   99.80 (+0.90%)
PFE   48.71 (-2.48%)
NFLX   244.94 (+0.34%)
S&P 500   4,231.93 (+0.52%)
DOW   33,507.23 (+0.59%)
QQQ   326.78 (+0.26%)
AAPL   169.49 (+0.15%)
MSFT   287.91 (-0.43%)
META   179.47 (+0.63%)
GOOGL   119.57 (-0.11%)
AMZN   141.76 (-0.65%)
TSLA   869.55 (-1.53%)
NVDA   183.56 (+1.43%)
NIO   21.44 (+6.93%)
BABA   95.51 (+3.33%)
AMD   100.77 (+1.74%)
MU   63.06 (+2.70%)
T   18.09 (+0.44%)
CGC   3.23 (-1.82%)
GE   78.71 (+2.04%)
F   15.68 (+1.16%)
DIS   118.88 (+5.74%)
AMC   25.08 (+5.96%)
PYPL   99.80 (+0.90%)
PFE   48.71 (-2.48%)
NFLX   244.94 (+0.34%)
S&P 500   4,231.93 (+0.52%)
DOW   33,507.23 (+0.59%)
QQQ   326.78 (+0.26%)
AAPL   169.49 (+0.15%)
MSFT   287.91 (-0.43%)
META   179.47 (+0.63%)
GOOGL   119.57 (-0.11%)
AMZN   141.76 (-0.65%)
TSLA   869.55 (-1.53%)
NVDA   183.56 (+1.43%)
NIO   21.44 (+6.93%)
BABA   95.51 (+3.33%)
AMD   100.77 (+1.74%)
MU   63.06 (+2.70%)
T   18.09 (+0.44%)
CGC   3.23 (-1.82%)
GE   78.71 (+2.04%)
F   15.68 (+1.16%)
DIS   118.88 (+5.74%)
AMC   25.08 (+5.96%)
PYPL   99.80 (+0.90%)
PFE   48.71 (-2.48%)
NFLX   244.94 (+0.34%)
NASDAQ:RCM

R1 RCM - RCM Stock Forecast, Price & News

$25.91
-0.14 (-0.54%)
(As of 08/11/2022 11:21 AM ET)
Add
Compare
Today's Range
$25.79
$26.23
50-Day Range
$19.31
$26.55
52-Week Range
$18.71
$27.86
Volume
15,447 shs
Average Volume
1.25 million shs
Market Capitalization
$7.25 billion
P/E Ratio
143.95
Dividend Yield
N/A
Price Target
$30.17

R1 RCM MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
15.8% Upside
$30.17 Price Target
Short Interest
Bearish
2.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.38mentions of R1 RCM in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
217.39%
From $0.23 to $0.73 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Business Services Sector

131st out of 338 stocks

Management Services Industry

2nd out of 7 stocks

RCM stock logo

About R1 RCM (NASDAQ:RCM) Stock

R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RCM. Deutsche Bank Aktiengesellschaft raised their target price on R1 RCM from $26.00 to $31.00 in a report on Thursday, August 4th. Guggenheim initiated coverage on R1 RCM in a report on Wednesday, April 13th. They set a "neutral" rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of R1 RCM in a research note on Monday, August 1st. They set an "overweight" rating for the company. Barclays restated an "overweight" rating and set a $29.00 target price on shares of R1 RCM in a research report on Wednesday, June 29th. Finally, TheStreet raised shares of R1 RCM from a "d" rating to a "c" rating in a report on Monday, May 9th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $30.17.

R1 RCM Stock Performance

RCM traded up $0.18 during trading hours on Wednesday, reaching $25.90. The company's stock had a trading volume of 60,114 shares, compared to its average volume of 1,257,141. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.57. The company's 50-day moving average is $22.52 and its 200-day moving average is $23.77. R1 RCM has a 52 week low of $18.71 and a 52 week high of $27.86. The firm has a market cap of $7.24 billion, a PE ratio of 142.90, a price-to-earnings-growth ratio of 6.16 and a beta of 0.91.

R1 RCM (NASDAQ:RCM - Get Rating) last released its quarterly earnings results on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). R1 RCM had a return on equity of 12.72% and a net margin of 3.98%. The firm had revenue of $385.70 million for the quarter, compared to analyst estimates of $384.18 million. During the same period in the previous year, the business posted ($2.37) earnings per share. The business's revenue for the quarter was up 12.6% on a year-over-year basis. On average, equities analysts forecast that R1 RCM will post 0.24 EPS for the current year.

Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

RCM Stock News Headlines

R1 RCM (NASDAQ:RCM) Coverage Initiated at JPMorgan Chase & Co.
R1 RCM Inc. (RCM) Tops Q2 Earnings Estimates
Recap: R1 RCM Q2 Earnings
R1 RCM Reports Second Quarter 2022 Results
R1 RCM Inc - Stock News
Sutter Health sells two Bay Area office buildings
R1 RCM Inc.: R1 RCM Completes Acquisition of Cloudmed
See More Headlines
Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

RCM Company Calendar

Last Earnings
11/02/2021
Today
8/11/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:RCM
CUSIP
00438V10
Employees
22,000
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$30.17
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+16.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$97.20 million
Pretax Margin
4.07%

Debt

Sales & Book Value

Annual Sales
$1.47 billion
Cash Flow
$0.64 per share
Book Value
$9.83 per share

Miscellaneous

Free Float
113,560,000
Market Cap
$7.25 billion
Optionable
Not Optionable
Beta
0.91

Social Links


Key Executives














RCM Stock - Frequently Asked Questions

Should I buy or sell R1 RCM stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RCM shares.
View RCM analyst ratings
or view top-rated stocks.

What is R1 RCM's stock price forecast for 2022?

7 brokers have issued twelve-month price objectives for R1 RCM's shares. Their RCM share price forecasts range from $27.00 to $34.00. On average, they predict the company's stock price to reach $30.17 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts price targets for RCM
or view top-rated stocks among Wall Street analysts.

How have RCM shares performed in 2022?

R1 RCM's stock was trading at $25.49 at the beginning of 2022. Since then, RCM shares have increased by 2.2% and is now trading at $26.05.
View the best growth stocks for 2022 here
.

When is R1 RCM's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our RCM earnings forecast
.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) announced its quarterly earnings results on Tuesday, November, 2nd. The healthcare provider reported $0.05 EPS for the quarter, missing the consensus estimate of $0.08 by $0.03. The healthcare provider earned $379.70 million during the quarter, compared to the consensus estimate of $372.87 million. R1 RCM had a net margin of 3.98% and a trailing twelve-month return on equity of 12.72%.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.85 billion-$1.87 billion, compared to the consensus revenue estimate of $1.87 billion.

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by many different institutional and retail investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (1.20%), Jennison Associates LLC (0.26%), SCW Capital Management LP (0.19%), Principal Financial Group Inc. (0.19%), Walleye Capital LLC (0.15%) and Oak Ridge Investments LLC (0.14%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends
.

How do I buy shares of R1 RCM?

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $26.05.

How much money does R1 RCM make?

R1 RCM (NASDAQ:RCM) has a market capitalization of $7.29 billion and generates $1.47 billion in revenue each year. The healthcare provider earns $97.20 million in net income (profit) each year or $0.18 on an earnings per share basis.

How many employees does R1 RCM have?

The company employs 22,000 workers across the globe.

Does R1 RCM have any subsidiaries?

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.
Read More

When was R1 RCM founded?

R1 RCM was founded in 2003.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The official website for the company is www.r1rcm.com. The healthcare provider can be reached via phone at (312) 324-7820, via email at arahim@r1rcm.com, or via fax at 302-655-5049.

This page (NASDAQ:RCM) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.